您的位置: 首页 » 法律资料网 » 法律法规 »

关于加强税务工商合作、实现股权转让信息共享的通知

时间:2024-06-30 16:04:44 来源: 法律资料网 作者:法律资料网 阅读:8248
下载地址: 点击此处下载

关于加强税务工商合作、实现股权转让信息共享的通知

国家税务总局 国家工商行政管理总局


关于加强税务工商合作 实现股权转让信息共享的通知

国税发[2011]126号


各省、自治区、直辖市和计划单列市国家税务局、地方税务局、工商行政管理局、市场监督管理局:
  为推进税务部门、工商行政管理部门之间的信息共享,强化股权转让税收征管,提升企业登记管理信息服务国家税收征管的能力,发挥税收调节收入分配的作用,现就加强税务、工商股权转让信息共享有关事项通知如下:
  一、信息共享的内容
  (一)工商行政管理部门向税务部门提供的信息
  有限责任公司已经在工商行政管理部门完成股权转让变更登记的股权转让相关信息,包括:营业执照注册号、公司名称、住所、股东姓名或者名称、股东证件类型、股东证件号码、股东出资额、出资比例、登记日期。
  (二)税务部门向工商行政管理部门提供的信息
  1.企业因股东转让股权在税务部门办理的涉税信息,包括营业执照注册号、企业名称、纳税人识别号、股东姓名或者名称、股东证件类型、股东证件号码。
  2.税务部门从工商行政管理部门获取公司股东转让股权变更登记信息后征收税款的有关信息,包括:营业执照注册号、纳税人姓名或者名称、纳税人识别号、税种、税款所属期、税款数额。
  二、信息共享的方式
   国家税务总局和国家工商行政管理总局建立信息共享平台和交换机制,开展股权变更登记信息共享工作。
  省及省以下各级国家税务局、地方税务局分别与同级工商行政管理局(市场监督管理局,下同)协商进行信息交换。要充分利用计算机网络交换信息,逐步确立信息化条件下的信息交换机制。有条件的地方,可以建立税务、工商信息共享平台,或者利用政府信息共享平台,进行信息集中交换。暂不能通过网络交换信息的,税务部门和工商行政管理部门可采用光盘等介质交换。
  三、信息共享的时限
  从2012年1月1日起,各级国家税务局、地方税务局和工商行政管理局应将每月发生的应交换信息,在当月终了15日内完成交换。2011年1月1日至2011年12月31日期间发生的应交换信息,在2012年6月30日之前完成交换。2010年1月1日至2010年12月31日期间发生的应交换信息,在2012年9月30日之前完成交换。
  四、加强组织协调
  省及省以下各级国家税务局、地方税务局和工商行政管理局要高度重视,积极向当地政府汇报有关工作,争取支持。要建立由国家税务局、地方税务局和工商行政管理局主要领导组成的信息共享领导协调小组,定期或者不定期召开联席会议,及时协调和解决信息共享工作中的问题。要严格落实相关保密制度,确保信息安全,对获取的相关信息,不得向税务部门、工商行政管理部门以外的第三方提供,擅自对外提供有关信息的,要承担相应的法律责任。要巩固已有的税务、工商合作成果,继续利用已有的政府信息共享平台,建立健全信息共享制度,探索税务、工商协调配合新模式。
  各省(自治区、直辖市和计划单列市)国家税务局会同地方税务局、工商行政管理局根据本通知的规定,制定具体的操作办法,于2012年2月底前报国家税务总局、国家工商行政管理总局备案。对《国家税务总局 国家工商行政管理总局关于工商登记信息和税务登记信息交换与共享问题的通知》(国税发[2003]81号)已规定的信息交换事项,继续执行。
  本通知自2012年1月1日起施行。


  国家税务总局 国家工商行政管理总局
  二○一一年十二月二十二日




Provisions for Drug Advertisement Examination

State Food and Drug Administration,State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.


关于印发《合肥市土地及宅基地整理和新农村建设项目市级补助资金管理暂行办法》的通知

安徽省合肥市财政局 合肥市国土资源局 合肥市新农村建设办公室


关于印发《合肥市土地及宅基地整理和新农村建设项目市级补助资金管理暂行办法》的通知

合财建[2008]219号


各县区财政局、国土资源局、新农办:

为保障我市土地及宅基地整理和新农村建设项目的顺利实施,规范财政资金使用,提高资金使用效益,根据国家和省有关规定,结合我市实际,特制定《合肥市土地及宅基地整理和新农村建设项目市级补助资金管理暂行办法》,现印发给你们,请遵照执行。





合肥市财政局 合肥市国土资源局 合肥市新农村建设办公室

二○○八年六月十九日



合肥市土地及宅基地整理和新农村建设项目市级补助资金管理暂行办法



第一章 总 则

第一条 为保障我市土地及宅基地整理和新农村建设项目的顺利实施,规范财政资金使用,提高资金使用效益,根据国家和省有关规定,结合本市实际,制定本办法。

第二条 本办法所称土地及宅基地整理和新农村建设项目(以下简称“宅基地整理项目”)市级补助资金,是指市财政从市级留成的新增建设用地有偿使用费、耕地开垦费和农业土地开发资金中安排,专项用于县、区宅基地整理项目建设补助的资金(以下简称“宅基地整理市级补助资金”),以及以宅基地整理项目为平台,市级整合的补助资金(以下简称“市级整合资金”)。

第三条 市对县、区宅基地整理项目按实际新增耕地面积给予补助。市级整合资金按《合肥市支持土地及宅基地整理和新农村建设资金整合办法》有关规定执行。

第四条 宅基地整理项目市级补助资金实行县、区“报账制”管理。项目所在县、区财政部门具体负责宅基地整理项目市级补助资金的收支、核算和监督管理工作。

第五条 宅基地整理项目市级补助资金必须专款专用,任何部门和单位不得截留、挤占和挪用。



第二章 宅基地整理项目市级补助资金的安排

第六条 各县区按照《合肥市土地及宅基地整理和新农村建设项目实施意见》的规定程序,组织编制宅基地整理项目规划设计和投资概算,报市国土资源局会同市财政局审核后,报市土委会审定。

第七条 对经市土委会批准实施的宅基地整理项目,农户旧宅基地复垦部分,按市国土资源局审定的新增耕地面积每亩5万元预安排补助资金;土地整理部分,按现有土地复垦整理政策标准执行。以上费用从市级留成的新增建设用地有偿使用费、耕地开垦费和农业土地开发资金中安排项目补助资金。

第八条 宅基地整理市级补助资金,专项用于农户拆迁补偿、新村基础设施建设、旧宅基地复垦整理以及项目实施范围内水利、林网、道路等农业生产基础设施建设支出,不得用于其他与宅基地复垦、整理及农业生产无关的支出。

第九条 宅基地整理市级补助资金不足或项目实施过程中由于不可预见因素等客观原因造成投资不足的,由项目所在县、区从留成的新增建设用地有偿使用费、耕地开垦费、农业土地开发资金及其他可用资金中安排解决,不得留有资金缺口。

第十条 市级整合资金,按《合肥市支持土地及宅基地整理和新农村建设资金整合办法》有关规定执行。

第十一条 宅基地整理项目所需工作经费按项目市级补助资金总额的3%比例,从市级留成的新增建设用地有偿使用费、耕地开垦费和农业土地开发资金中安排,用于对宅基地整理项目前期工作经费及管理费用补助。市级整合资金不得开支项目工作经费及管理费用。具体资金使用管理办法另行制定。



第三章 市级补助资金的拨付

第十二条 宅基地整理市级补助资金拨付,按以下原则办理:

(一)宅基地整理项目招标工作完成后,市财政局根据市国土资源局下达的项目开工批复,按项目补助资金总额的30%比例拨付资金。

(二)项目实施过程中,县、区根据项目实施进度及资金使用情况,凭项目监理单位签字的工程进度证明,向市国土资源局提出资金申请,市国土资源局审核后提出资金支付意见,市财政局审核后办理资金支付手续。招标工程进度达到50%、70%、竣工验收合格后,市财政分别按达到项目补助资金预算的45%、65%、80%比例审核拨付资金;旧宅基地复垦完成并经市国土资源局验收合格后,市财政按达到项目补助资金预算的90%比例审核拨付资金。

第十三条 宅基地整理项目经省国土资源厅验收后,市财政按省国土资源厅确认的新增耕地面积办理资金清算。超过计划新增耕地面积的,按5万元/亩标准增加补助;少于计划新增耕地面积的,按5万元/亩标准扣减补助资金。多拨资金的,由县、区财政缴回市财政;拒不缴回的,由市财政从对县、区的转移支付资金中扣回。

第十四条 市级整合资金拨付,按以下原则办理:

(一)实行工程建设招标的项目,在项目完成招标,开工建设后,按中标合同拨付30%的启动资金,项目建设过程中,按工程进度审核拨付资金。

(二)实行先建后补的项目,在项目建成并通过市级有关部门验收合格后,拨付补助资金。

(三)对生产发展类项目,按市级有关项目资金管理办法执行。

第十五条 市财政对项目前期工作经费及管理费用补助资金,开工时预拨60%,竣工验收后拨付剩余的40%。



第四章 资金核算与管理

第十六条 宅基地整理项目所在县、区财政应按照“报帐制”管理规定,设立专户,对财政补助资金实行专户管理、专帐分项目核算、资金封闭运行、专款专用。

第十七条 宅基地整理项目前期工作经费及管理费用市级补助资金,要本着节约的原则使用,不得用于人员经费及其他与项目无关的开支,资金如有结余,统筹用于项目建设。

第十八条 县、区财政要按照有关制度和财务管理规定,建立健全宅基地整理项目资金管理及财务核算、审批等制度,健全监督制约机制,严格审核把关,严格按用途使用财政补助资金,完善相关手续,确保资金安全、使用合规、核算规范。



第五章 监督与检查

第十九条 市财政、国土等相关部门要不定期对项目资金使用、工程进度等情况进行专项检查,发现问题,及时处理。

第二十条 宅基地整理项目竣工后,市财政局要会同市国土资源局通过公开招标,委托具有资质的中介机构对项目竣工财务决算进行审计,并根据审计结果办理资金清算。对截留、挤占、挪用市级补助资金的,要予以纠正或由市财政扣回;情节严重的,移交有关部门处理。



第六章 附 则

第二十一条 本办法自下发之日起施行,有效期三年。